Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight, compared...
Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
Drug Therapy01:28

Drug Therapy

The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The future of diagnostics in Africa.

Nature medicine·2026
Same author

Remodeling of Metabolic and Secretory Organelles During Oncogenic and Oncomodulatory Viral Infections.

Viruses·2026
Same author

The anti-viral protein Shiftless blocks p-body formation during KSHV infection.

The Journal of general virology·2026
Same author

Methylphenidate reduces rats' temporal discounting of aversive outcomes.

Psychopharmacology·2026
Same author

Postoperative Instruction Retention, Written Versus Audiovisual Adjuncts: A Prospective Randomized Study.

Journal of hand surgery global online·2024
Same author

Focused stimulation of dorsal versus ventral subthalamic nucleus enhances action-outcome learning in patients with Parkinson's disease.

Brain communications·2024

Related Experiment Videos

Drug therapy in pediatrics: a developing field.

Lisa Mathis1, William Rodriguez

  • 1Office of New Drugs, FDA, Silver Spring, Maryland 20903, USA. lisa.mathis@fda.hhs.gov

Dermatologic Therapy
|May 21, 2009
PubMed
Summary
This summary is machine-generated.

Pediatric drug studies were historically lacking, leading to empiric dosing. New legislation now mandates pediatric drug studies, enabling evidence-based treatments for children.

Related Experiment Videos

Area of Science:

  • Pediatric pharmacology and regulatory science.

Background:

  • Historically, drug therapies lacked explicit study in pediatric populations, necessitating empiric treatment and raising safety concerns.
  • Dermatologic conditions are prevalent in children, highlighting the need for evidence-based therapeutic options.

Purpose of the Study:

  • To review the historical lack of pediatric drug data and the legislative changes that now enable evidence-based treatment.

Main Methods:

  • Review of historical practices and legislative milestones in pediatric drug development.
  • Analysis of the impact of new regulations on pediatric clinical trials and data availability.

Main Results:

  • Legislation in 1998 and subsequent laws empowered the Food and Drug Administration (FDA) to require pediatric studies.
  • Improved understanding of pediatric-specific dose-effectiveness and safety profiles is now achievable.

Conclusions:

  • New legislation and a better understanding of pediatric pharmacology have transitioned treatment from empiric to evidence-based.
  • This shift allows for safer and more effective dermatologic and other treatments in children.